Eleonora Dondossola, Ph.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Regular Member, Institutional Committee, (Cancer Biology, Therapeutics and Pharmacology Programs), the Graduate School of Biomedical Sciences, UT MDACC, Houston, Tx, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2010 | University Vita-Salute San Raffaele, Milan, IT, Cell and Molecular Biology, Ph.D |
| 2006 | University Vita-Salute San Raffaele, Milan, IT, Molecular and Cellular Medical Biotechnology, M.Sc |
| 2004 | University Vita-Salute San Raffaele, Milan, IT, Medical and Pharmaceutical Biotechnology, B.Sc |
Postgraduate Training
| 2013-2016 | Postdoctoral Fellow, Cancer Biology Intravital Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2013 | Postdoctoral Fellow, Tumor Angiogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2010-2011 | Postdoctoral Fellow, Tumor Vessel Biology, San Raffaele Scientific Institute, Milan |
Experience & Service
Faculty Academic Appointments
Instructor, Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2022
Lecturer, University Vita-Salute San Raffaele, Milan, 2008 - 2024
Other Professional Positions
Adjunct Faculty, Department of Bioengineering, Rice University, Houston, TX, 2023 - Present
Extramural Institutional Committee Activities
Chair, Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Search Committee, Department of Bioengineering, Rice University, 2024 - Present
Co-Chair, RFA Task Force, The University of Texas MD Anderson Cancer Center, 2024 - Present
Chair-elect, Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2024
Co-Chair, Italian Scientists and Scholars in North America Foundation, West South - Central Chapter, The University of Texas MD Anderson Cancer Center, 2022 - Present
Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Communication Vice Chair, Postdoctoral Association Executive Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2016
Editorial Activities
Journal Reviewer, Science Translational Medicine; Nature Communications; the Journal of Experimental Medicine; Advanced Healthcare Materials; Trends in Biotechnology; ACS Biomaterials Science & Engineering; ACS Applied Materials & Interfaces; Cancers; Scientific Reports; BBA - Molecular Cell Research; Bone Research; Communications Biology; Tissue Engineering Part C, 2018
Honors & Awards
| 2023 | AACR Early Stage Investigator Scholar Award, AACR Annual Meeting, Inaugural Class |
| 2021 | 40 Under 40 in Cancer, The Lynx Group, Upstream Partners, the Association for Value-Based Cancer Care, NCODA, and Swim Across America |
| 2019 | Nature Research Award for Inspiring Science - Top 10 Finalist |
| 2017 | The Rolanette and Berdon Lawrence Bone Research Award, The Rolanette and Berdon Lawrence Bone Disease Program of Texas |
| 2017 | Selected as part of the 100 Italian Influential Women in STEM https://100esperte.it/search?id=302 |
| 2016 | The 2016 Mark Walter, Brent Nicklas, Adrianne and Jerry Cohen–PCF Young Investigator Award, Prostate Cancer Foundation |
| 2015 | Gerald B. Grindey Memorial Scholar-in-Training Award, AACR |
| 2015 | The Lupe C. Garcia Fellowship in Cancer Research, University of Texas MD Anderson Cancer Center |
| 2015 | AFLAC Scholar-in-Training Award, AACR-Tumor Metastasis Special Conference |
| 2014 | Travel grant, 2014 ISSNAF Young Investigator Awards - Biomedicine, Italian Embassy, Washington |
| 2014 | The AMGEN Award in Basic Science Research, University of Texas MD Anderson Cancer Center |
| 2014 | Individual Investigator Award, Cancer Prevention and Research Institute of Texas (CPRIT) |
| 2014 | Descience Contest - finalist, MIT Media Lab |
| 2007 - 2009 | Ministerial Research Fellowship, Italian Ministry of School and Research |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2025. Tissue-engineered models for cancer. Conference. Presented at the 32nd Advances in Tissue Engineering Short Course, US.
- 2025. Integrated modeling of bone metastasis to dissect and overcome cancer therapy failure. Presented at the Preclinical Imaging Consortium Conference, US.
- 2024. Integrated modeling of bone metastasis to dissect and overcome cancer therapy failure. Presented at the 59th, Texas Microscopy Society Meeting, US.
- 2024. Integrated modeling of bone metastasis to dissect and overcome cancer therapy failure. Presented at the MDA, Spatial Biology: Multiplex, Multi-omics Seminar, US.
- 2024. Tissue-engineered models for cancer. Presented at the 31st Advances in Tissue Engineering Short Course, US.
- 2023. Tissue-engineered models for cancer. Conference. Tissue-engineered models for cancer, US.
- 2023. The bone metastasis immunological niche: unraveling its complexity and role in therapy response and resistance. Conference. The bone metastasis immunological niche: unraveling its complexity and role in therapy response and resistance, US.
- 2023. Mentor in AACR Special Programs for Undergraduate and High School Students. Conference. Mentor in AACR Special Programs for Undergraduate and High School Students. Orlando, FL, US.
- 2023. Networking events for Italian Scientists in Houston. Conference. Networking events for Italian Scientists in Houston. Houston, TX, US.
- 2022. Tissue-engineered models for cancer. Conference. Tissue-engineered models for cancer, US.
- 2021. Integration of tissue-engineered models of prostate cancer bone metastasis with intravital imaging and computational modeling reveals Radium 223 zonal cytotoxicity. Conference. Integration of tissue-engineered models of prostate cancer bone metastasis with intravital imaging and computational modeling reveals Radium 223 zonal cytotoxicity, US.
- 2020. Modeling and monitoring cell partners of progression and therapy response in prostate cancer bone metastasis. Conference. Modeling and monitoring cell partners of progression and therapy response in prostate cancer bone metastasis. Houston, TX, US.
- 2019. Tissue engineered tumor models. Conference. Tissue engineered tumor models. Houston, TX, US.
- 2019. Modeling and targeting metastatic progression in bone. Conference. The Leo and Anne Albert Charitable Trust. San Diego, CA, US.
- 2017. 7th Annual Postdoctoral Scientific Symposium. Conference. 7th Annual Postdoctoral Scientific Symposium. Houston, TX, US.
- 2014. Promotion of Science through fashion,. Conference. Promotion of Science through fashion,. Boston, MA, US.
- 2014. Promotion of Science through fashion,. Conference. Promotion of Science through fashion,. Boston, MA, US.
International Presentations
- 2023. Career development symposium. Conference. Career development symposium. Milan, IT.
- 2023. Co-organizer of the Italian Research Day in the World 2023 in collaboration with the Italian Consulate. Conference. Co-organizer of the Italian Research Day in the World 2023 in collaboration with the Italian Consulate. Houston, US.
- 2022. Mind the STEM Gap. Conference. Mind the STEM Gap, AE.
- 2022. Video/text content creation for high school students for the International day of girls and women in science. Conference. Video/text content creation for high school students for the International day of girls and women in science, US.
- 2015. Multiphoton Microscopy. ICCHB 2015. Conference. ICCHB 2015, AT.
Formal Peers
- 2024. Integrated modeling of bone metastasis to dissect and overcome cancer therapy failure. Houston, Texas, US.
- 2024. Integrated modeling of bone metastasis to dissect and overcome cancer therapy failure. Houston, Texas, US.
- 2023. Integrated modeling of bone metastasis to dissect and overcome cancer therapy failure. Houston, Texas, US.
- 2023. Modeling and targeting of bone metastatic prostate cancer. Invited. Milan, IT.
- 2023. Bone Metastasis: A Paradigm Towards Understanding Dynamic and Microenvironment-Dependent Prostate Cancer Progression. Houston, Texas, US.
- 2022. Modeling and targeting bone metastatic prostate cancer. Invited, US.
- 2021. Radium 223 mediates zonal toxicity of prostate cancer cells in bone. Invited, US.
- 2021. Monitoring cell partners of progression and therapy response in prostate cancer bone metastasis. Invited, US.
- 2020. Intravital Multiphoton Microscopy: Real-Time Disease Modeling with Biofabricated Tissues. Invited. Houston, TX, US.
- 2019. Monitoring cell partners of progression and therapy response in prostate cancer bone metastasis. Invited, US.
- 2018. Monitoring cell partners of progression and therapy response in prostate cancer bone metastasis. Invited. Seattle, WA, US.
- 2018. Bone formation and foreign body response, two sides of the same polycaprolactone scaffold. Invited. Houston, TX, US.
- 2017. A de-scientific experience. Invited. Houston, TX, US.
- 2017. Monitoring cell partners of progression and therapy response in prostate cancer bone metastasis. Invited. Houston, TX, US.
- 2017. Intravital microscopy of prostate cancer lesions in bone: kinetics of osteolysis and therapy response. Invited. Houston, TX, US.
- 2017. Bone formation and foreign body response, two sides of the same polycaprolactone scaffold. Invited. Houston, TX, US.
- 2017. Monitoring cell partners of progression and therapy response in prostate cancer bone metastasis. Invited, Milan, IT.
- 2015. A tissue-engineered bone model for preclinical intravital multiphoton microscopy of prostate cancer lesions. Invited. Houston, TX, US.
- 2014. A tissue-engineered bone model for preclinical intravital multiphoton microscopy of prostate cancer lesions. Invited, Milan, IT.
Grant & Contract Support
| Date: | 2026 - 2027 |
| Title: | Defining and targeting spatiotemporal mechanisms of response and resistance to immunotherapy and tyrosine kinase inhibitors in clear cell renal cell carcinoma bone metastases |
| Funding Source: | Kidney Cancer Association |
| Role: | PI |
| Date: | 2026 - 2031 |
| Title: | Illuminating Bone-Controlled Immunobiology in Metastatic Progression and Therapy Resistance |
| Funding Source: | Cancer Research Institute (CRI) |
| Role: | PI |
| ID: | CRI17315 |
| Date: | 2026 - 2031 |
| Title: | Therapeutic Resistance in Renal Cell Carcinoma Bone Metastases: Mechanisms and Targeted Interventions |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | PA-25-301 |
| Date: | 2026 - 2031 |
| Title: | Illuminating the Immune Dynamics of Metastatic Renal Cell Carcinoma to Bone |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | CA307210-01A1 |
| Date: | 2025 - 2030 |
| Title: | Dissecting the Effects of Radium 223 on Bone Health |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | CA291755-01A1 |
| Date: | 2025 - 2030 |
| Title: | Bioengineered lymphatic regenerating platform for treatment of breast cancer related lymphedema |
| Funding Source: | R01, NIH/NCI |
| Role: | Co-I |
| ID: | 1R01HL179534-01 |
| Date: | 2023 - 2026 |
| Title: | Overcoming Therapy Resistance by Integrated Computational Modeling of The Bone Metastatic Niche in Prostate and Renal Cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP230160 |
| Date: | 2022 - 2025 |
| Title: | The Bone Metastasis Immunological Niche: Unraveling its Complexity and Role in Therapy Response and Resistance |
| Funding Source: | DOD |
| Role: | PI |
| ID: | W81XWH-22-1-0466 |
| Date: | 2022 - 2024 |
| Title: | Integrating In vivo and In Silico Models of Prostate Cancer-Bone Interactions to Overcome Anti-Tumor Therapy Resistance |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | CA267312-02 |
| Date: | 2021 - 2026 |
| Title: | Investigation of the Role of Epithelial-Mesenchymal Plasticity in Renal Cell Carcinoma |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | CA258226-04 |
| Date: | 2020 - 2023 |
| Title: | Targeting the Osteogenic Niche for Preventing Kidney Cancer Bone Metastasis Progression |
| Funding Source: | DOD-KCRP |
| Role: | Co-I |
| ID: | KC190205, W81XWH-20-1-0895 |
| Date: | 2020 - 2021 |
| Title: | Tissue Engineered Platforms Combined to ex vivo PDX Engineering and Direct in vivo Transfer for Co - Clinical strategies |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P50 CA140388-10-Development Research Program DRP |
| Date: | 2020 - 2027 |
| Title: | Dissecting Radium 223 Mechanisms of Action and Therapeutic Efficacy in Preclinical Models of Prostate Cancer Lesions in Bone |
| Funding Source: | Bayer |
| Role: | PI |
| ID: | 57440 |
| Date: | 2020 - 2022 |
| Title: | Targeting the Osteogenic Niche in the AML Bone Marrow Microenvironment Using ALK 2 Inhibitor TP-0184 |
| Funding Source: | Tolero Pharmaceuticals, Inc |
| Role: | Co-I |
| ID: | RCTS 57799 |
| Date: | 2019 - 2021 |
| Title: | Illuminating the Resistance Niche to Chemotherapy in Osteosarcoma |
| Funding Source: | Alex Lemonade Stand Foundation |
| Role: | Co-I |
| Date: | 2019 - 2021 |
| Title: | Targeting Kinases in Castration-Resistant Prostate Cancer Bone Metastasis |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | PI |
| ID: | 633640 |
| Date: | 2019 - 2021 |
| Title: | Effect of AP-002 on cancer bone metastases and bone resorption |
| Funding Source: | Altum Pharmaceuticals Inc |
| Role: | PI |
| Date: | 2018 - 2020 |
| Title: | Targeting Metabolic Vulnerabilities in Metastatic Prostate Cancer to Bone |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P50 CA140388-09 |
| Date: | 2017 - 2018 |
| Title: | Targeting Kinases and Associated Networks in Metastatic Castrate-Resistant Prostate Cancer. Interdisciplinary Approaches in Cancer Metastasis |
| Funding Source: | Sage Bionetworks/National Cancer Institute |
| Role: | Co-I |
| ID: | U24 CA209923-02 |
| Date: | 2017 - 2022 |
| Title: | Programs of Prostate Cancer Invasion into Bone: Morphological, Molecular and Therapeutic Consequences |
| Funding Source: | The Rolanette and Berdon Lawrence Bone Disease Program of Texas |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | Preclinical Targeting of Early-Stage and Established Prostate Cancer Lesions in Bone by Radium-223: Impact on Tumor Cells, Stroma and Markers of Response |
| Funding Source: | Prostate Cancer Foundation |
| Role: | PI |
| ID: | 16YOUN24 |
| Date: | 2014 - 2017 |
| Title: | Preclinical Intravital Microscopy of Prostate Cancer Lesions in Bone: Identification and Eradication of Survival Niches by Combination Therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP140482 |
Selected Publications
Peer-Reviewed Articles
- Wang, Y, Casarin, S, Daher, M, Mohanty, V, Dede, M, Shanley, M, Dondossola, E, La Posta, L, Basar, R, Rezvani, K, Chen, KS. Agent-based modeling of cellular dynamics in adoptive cell therapy. Communications Biology 9(1), 2026. e-Pub 2026. PMID: 41673469.
- Zacharias NM, Rupe ES, Chen X, Kotecha RR, Rieke DT, McGregor BA, Pesquera P, Yu Z, Grover A, Daw NC, Wang E, Chan SWS, Douglas-Lindsay D, Fan AC, Knoche EM, Kyriakopoulos CE, Lalani AA, Mantia CM, Merla A, Voss MH, Pfanzelter N, Ramakrishna S, Reaume NM, Tang T, Ingram DR, Shamsutdinova D, Wani KM, Wang WL, Lazar AJ, Sheth RA, Rao P, Grimm SL, Coarfa C, He R, Qian J, Duan F, Bisht D, Chauhan PK, Perelli L, Genovese G, Yang L, Lin C, Karam JA, La Posta L, Dondossola E, Basar R, Uprety N, Rezvani K, Gao J, Wang L, Solis Soto LM, Lim B, Tannir NM, Karki M, Msaouel P. Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity. Clin Cancer Res, 2026. e-Pub 2026. PMID: 42627757.
- Li Y, Fan H, Wang G, Wang X, Basar R, Munir MN, Uprety N, Shrestha R, La Posta L, Liu B, Wilson J, Menon P, Fowlkes NW, Zhang P, Liu E, Deyter GM, Muniz-Feliciano L, Banerjee PP, Daher M, Marin D, Dondossola E, Varadarajan N, Shpall EJ, Rezvani K. Depletion of an immature cord blood NK subset reverses trogocytosis-driven CAR NK dysfunction. Cancer Cell, 2026. e-Pub 2026. PMID: 42526444.
- Montoya, A, Frank, ML, Jiang, P, Nie, H, Zhang, M, Bontekoe, E, Slone, J, Posta, LL, Sorice, SC, Cascone, T, Gillison, M, Gibbons, DL, Zhang, J, Dondossola, E, Kavraki, LE, Wenzel, P, Heymach, JV, Reuben, A. Unbiased avidity-based isolation of antigen-specific T cells. Journal for immunotherapy of cancer 14(7), 2026. e-Pub 2026. PMID: 42419878.
- Allegri, G, Pavirani, L, Barrios, S, Sorice, SC, Alessandrelli, G, Marsilio, L, Mikos, AG, Cerveri, P, Casarin, S, Dondossola, E. Bo-Net. PloS one 21(8):e0353796, 2026. e-Pub 2026. PMID: 42550873.
- Barrios, S, Serafini, E, La Posta, L, Meyers, DN, Dunbar, NJ, Corn, P, Elefteriou, F, Ambrose, CG, Casarin, S, Mikos, AG, Dondossola, E. Dissecting the effects of223Radium on the bone microenvironment. Acta Pharmaceutica Sinica B 15(10):5010-5021, 2025. e-Pub 2025. PMID: 41132855.
- Marsilio L, Barrios S, Maksimovic S, Maccarini A, Serafini E, Grimaldi M, Heyman TJ, Cerveri P, Casarin S, Dondossola E. In silico Digital Twins of Bone Metastasis Enable Investigation of Tumor Progression and Therapy Response. Cancer Research 85(21):4269-4284, 2025. e-Pub 2025. PMID: 40965325.
- Maksimovic S, Boscolo NC, La Posta L, Barrios S, Moussa MJ, Gentile E, Pesquera PI, Li W, Chen J, Gomez JA, Basi A, Burks JK, Alvarez-Breckenridge C, Gao J, Campbell MT, Dondossola E. Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone. Cancer Res Commun 4(10):2621-2637, 2024. e-Pub 2024. PMID: 39248577.
- Paindelli C, Parietti V, Barrios S, Shepherd P, Pan T, Wang WL, Satcher RL, Logothetis CJ, Navone N, Campbell MT, Mikos AG, Dondossola E. Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo. Acta Biomater 178:83-92, 2024. e-Pub 2024. PMID: 38387748.
- Stanford SM, Nguyen TP, Chang J, Zhao Z, Hackman GL, Santelli E, Sanders CM, Katiki M, Dondossola E, Brauer BL, Diaz MA, Zhan Y, Ramsey SH, Watson PA, Sankaran B, Paindelli C, Parietti V, Mikos AG, Lodi A, Bagrodia A, Elliott A, McKay RR, Murali R, Tiziani S, Kettenbach AN, Bottini N. Targeting prostate tumor low-molecular weight tyrosine phosphatase for oxidation-sensitizing therapy. Sci Adv 10(5):eadg7887, 2024. e-Pub 2024. PMID: 38295166.
- Bektemessov, Z, Cherfils, L, Allery, C, Berger, J, Serafini, E, Dondossola, E, Casarin, S. On a data-driven mathematical model for prostate cancer bone metastasis. AIMS Mathematics 9(12):34785-34805, 2024. e-Pub 2024.
- Soeung M, Perelli L, Chen Z, Dondossola E, Ho IL, Carbone F, Zhang L, Khan H, Le CN, Zhu C, Peoples MD, Feng N, Jiang S, Zacharias NM, Minelli R, Shapiro DD, Deem AK, Gao S, Cheng EH, Lucchetti D, Walker CL, Carugo A, Giuliani V, Heffernan TP, Viale A, Tannir NM, Draetta GF, Msaouel P, Genovese G. SMARCB1 regulates the hypoxic stress response in sickle cell trait. Proc Natl Acad Sci U S A 120(21):e2209639120, 2023. e-Pub 2023. PMID: 37186844.
- Mossa F, Robesti D, Sumankalai R, Corey E, Titus M, Kang Y, Zhang J, Briganti A, Montorsi F, Vellano CP, Marszalek JR, Frigo DE, Logothetis CJ, Gujral TS, Dondossola E. Subtype and site specific-induced metabolic vulnerabilities in prostate cancer. Mol Cancer Res 21(1):51-61, 2023. e-Pub 2023. PMID: 36112348.
- Parlani M, Bedell ML, Mikos AG, Friedl P, Dondossola E. Dissecting the recruitment and self-organization of αSMA-positive fibroblasts in the foreign body response. Sci Adv 8(51):eadd0014, 2022. e-Pub 2022. PMID: 36542704.
- Parlani M, Boccalatte F, Yeaton A, Wang F, Zhang J, Aifantis I, Dondossola E. Radium 223 induces transient functional bone marrow toxicity. J Nucl Med 63(10):1544-1550, 2022. e-Pub 2022. PMID: 35177425.
- Paindelli C, Casarin S, Wang F, Diaz-Gomez L, Zhang J, Mikos AG, Logothetis CJ, Friedl P, Dondossola E. Enhancing Radium 223 treatment efficacy by anti-beta 1 integrin targeting. J Nucl Med 63(7):1039-1045, 2022. e-Pub 2022. PMID: 34711616.
- Sarti, M, Parlani, M, Diaz-Gomez, LA, Mikos, AG, Cerveri, P, Casarin, S, Dondossola, E. Deep Learning for Automated Analysis of Cellular and Extracellular Components of the Foreign Body Response in Multiphoton Microscopy Images. Frontiers in Bioengineering and Biotechnology 9, 2022. e-Pub 2022. PMID: 35145962.
- Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34885132.
- Bello T, Paindelli C, Diaz-Gomez LA, Melchiorri A, Mikos AG, Nelson PS, Dondossola E, Gujral TS. Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer. Proc Natl Acad Sci U S A 118(40), 2021. e-Pub 2021. PMID: 34593636.
- Casarin S, Dondossola E. An agent-based model of prostate Cancer bone metastasis progression and response to Radium223. BMC Cancer 20(1):605, 2020. e-Pub 2020. PMID: 32600282.
- Dondossola E, Casarin S, Paindelli C, De-Juan-Pardo EM, Hutmacher DW, Logothetis CJ, Friedl P. Radium 223-Mediated Zonal Cytotoxicity of Prostate Cancer in Bone. J Natl Cancer Inst 111(10):1042-1050, 2019. e-Pub 2019. PMID: 30657953.
- Paindelli C, Navone N, Logothetis CJ, Friedl P, Dondossola E. Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro. Biomaterials 197:296-304, 2019. e-Pub 2019. PMID: 30682644.
- Dondossola E, Alexander S, Holzapfel BM, Filippini S, Starbuck MW, Hoffman RM, Navone N, De-Juan-Pardo EM, Logothetis CJ, Hutmacher DW, Friedl P. Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Sci Transl Med 10(452), 2018. e-Pub 2018. PMID: 30068572.
- Dondossola E, Holzapfel BM, Alexander S, Filippini S, Hutmacher DW, Friedl P. Dissecting the foreign body response to biomaterials by non-linear intravital microscopy. Nat Biomed Eng 1(0007), 2016. e-Pub 2016.
- Curnis F, Dallatomasina A, Bianco M, Gasparri A, Sacchi A, Colombo B, Fiocchi M, Perani L, Venturini M, Tacchetti C, Sen S, Borges R, Dondossola E, Esposito A, Mahata SK, Corti A. Regulation of tumor growth by circulating full-length chromogranin A. Oncotarget 7(45):72716-72732, 2016. e-Pub 2016. PMID: 27683038.
- Bianco M, Gasparri A, Generoso L, Assi E, Colombo B, Scarfò L, Bertilaccio MT, Scielzo C, Ranghetti P, Dondossola E, Ponzoni M, Caligaris-Cappio F, Ghia P, Corti A. Inhibition of chronic lymphocytic leukemia progression by full length chromogranin A and its N-terminal fragment in mouse models. Oncotarget. e-Pub 2016. PMID: 27203389.
- Dondossola E, Dobroff AS, Marchiò S, Cardó-Vila M, Hosoya H, Libutti SK, Corti A, Sidman RL, Arap W, Pasqualini R. Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors. Proc Natl Acad Sci U S A 113(8):2223-8, 2016. e-Pub 2016. PMID: 26858439.
- Mintz PJ, Rietz AC, Cardó-Vila M, Ozawa MG, Dondossola E, Do KA, Kim J, Troncoso P, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer. Proc Natl Acad Sci U S A 112(8):2515-20, 2015. e-Pub 2015. PMID: 25675522.
- Christianson DR, Dobroff AS, Proneth B, Zurita AJ, Salameh A, Dondossola E, Makino J, Bologa CG, Smith TL, Yao VJ, Calderone TL, O'Connell DJ, Oprea TI, Kataoka K, Cahill DJ, Gershenwald JE, Sidman RL, Arap W, Pasqualini R. Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. Proc Natl Acad Sci U S A 112(8):2521-6, 2015. e-Pub 2015. PMID: 25659743.
- Dondossola E, Corti A, Sidman RL, Arap W, Pasqualini R. Bone marrow-derived CD13(+) cells sustain tumor progression: A potential non-malignant target for anticancer therapy. Oncoimmunology 3:e27716, 2014. e-Pub 2014. PMID: 25339996.
- Dondossola E, Rangel R, Guzman-Rojas L, Barbu EM, Hosoya H, St John LS, Molldrem JJ, Corti A, Sidman RL, Arap W, Pasqualini R. CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A 110(51):20717-22, 2013. e-Pub 2013. PMID: 24297924.
- Dondossola E, Crippa L, Colombo B, Ferrero E, Corti A. Chromogranin A regulates tumor self-seeding and dissemination. Cancer Res 72(2):449-59, 2012. e-Pub 2012. PMID: 22139379.
- Guzman-Rojas L, Rangel R, Salameh A, Edwards JK, Dondossola E, Kim YG, Saghatelian A, Giordano RJ, Kolonin MG, Staquicini FI, Koivunen E, Sidman RL, Arap W, Pasqualini R. Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proc Natl Acad Sci U S A 109(5):1637-42, 2012. e-Pub 2012. PMID: 22307623.
- Veschini L, Crippa L, Dondossola E, Doglioni C, Corti A, Ferrero E. The vasostatin-1 fragment of chromogranin A preserves a quiescent phenotype in hypoxia-driven endothelial cells and regulates tumor neovascularization. FASEB J 25(11):3906-14, 2011. e-Pub 2011. PMID: 21825034.
- Dondossola E, Gasparri AM, Colombo B, Sacchi A, Curnis F, Corti A. Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy. Cancer Res 71(17):5881-90, 2011. e-Pub 2011. PMID: 21799030.
- Roatta S, Passatore M, Novello M, Colombo B, Dondossola E, Mohammed M, Losano G, Corti A, Helle KB. The chromogranin A- derived N-terminal peptide vasostatin-I: In vivo effects on cardiovascular variables in the rabbit. Regul Pept 168(1-3):10-20, 2011. e-Pub 2011. PMID: 21362443.
- Dondossola E, Gasparri A, Bachi A, Longhi R, Metz-Boutigue MH, Tota B, Helle KB, Curnis F, Corti A. Role of vasostatin-1 C-terminal region in fibroblast cell adhesion. Cell Mol Life Sci 67(12):2107-18, 2010. e-Pub 2010. PMID: 20217454.
- Curnis F, Longhi R, Crippa L, Cattaneo A, Dondossola E, Bachi A, Corti A. Spontaneous formation of L-isoaspartate and gain of function in fibronectin. J Biol Chem 281(47):36466-76, 2006. e-Pub 2006. PMID: 17015452.
Review Articles
- Hahn, AW, Siddiqui, BA, Leo, J, Dondossola, E, Basham, KJ, Miranti, CK, Frigo, DE. Cancer Cell–Extrinsic Roles for the Androgen Receptor in Prostate Cancer. Endocrinology 164(6), 2023. e-Pub 2023. PMID: 37192413.
- Leo J, Dondossola E, Basham KJ, Wilson NR, Alhalabi O, Gao J, Kurnit KC, White MG, McQuade JL, Westin SN, Wellberg EA, Frigo DE. Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer. Endocrinology 164(6), 2023. e-Pub 2023. PMID: 37154098.
- Dondossola E, Friedl P. Host responses to implants revealed by intravital microscopy. Nature Review Material 7 (1):p. 6-22, 2022. e-Pub 2022.
- Sheth RA, Perkons N, Dondossola E, Subudhi SK, Gade TP, Tam AL. Patient-Derived Xenograft Tumor Models: Overview and Relevance to IR. J Vasc Interv Radiol 29(6):880-882.e1, 2018. e-Pub 2018. PMID: 29798759.
Book Chapters
- Dondossola E, Paindelli C. In vitro 3D modeling for prostate cancer. In: Biomaterials for 3D Tumor Modeling. Elsevier, 2020.
Patient Reviews
CV information above last modified September 04, 2026